SynthesisAlimentary pharmacology & therapeutics2016
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.
Synthesis in Alimentary pharmacology & therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.Clinical and molecular hepatology · 2024Guideline
- Trial
- Performance of Serum-Based Non-Invasive Fibrosis Scores Compared with Liver Biopsy in Patients with Chronic Hepatitis B.Medicina (Kaunas, Lithuania) · 2026Article
- Aspartate aminotransferase-to-platelet ratio index (APRI) for staging of fibrosis in adults with chronic hepatitis C.The Cochrane database of systematic reviews · 2025Article
- Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.World journal of hepatology · 2025Article
- Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients.Scientific reports · 2024Article
- [Serological Markers to Assess Liver Fibrosis and Their Roles].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- [Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- Prognostic Value of Fibrosis 4 (FIB-4) Index in Sepsis Patients.Journal of personalized medicine · 2024Article
- Autoimmune Hepatitis and Fibrosis.Journal of clinical medicine · 2023Review
- Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection.Biomedical journal · 2022Article
- Gene therapy: Practical aspects of implementation.Haemophilia : the official journal of the World Federation of Hemophilia · 2022Review
- Liver fibrosis quantification.Abdominal radiology (New York) · 2022Review
- External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B.Gastro hep advances · 2022Article
- Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.Alimentary pharmacology & therapeutics · 2021Article
- Comparison between shear wave elastography and serological findings for the evaluation of fibrosis in chronic liver disease.Journal of ultrasonography · 2021Article
- External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.JHEP reports : innovation in hepatology · 2021Article
- Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy.Experimental and therapeutic medicine · 2021Article
- Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.Clinics and research in hepatology and gastroenterology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood tests and transient elastography (TE), proposed as alternatives to biopsy for identifying advanced fibrosis (METAVIR-stage-F2 or greater) or cirrhosis, have never been compared using an intention to diagnose approach, with direct comparisons only, and Bayesian approach.
aimTo permit more appropriate comparisons.
methodsFrom an overview of articles (2002-2014), we selected studies that directly compared the diagnostic accuracy of FibroTest, aspartate aminotransferase-platelet ratio index (APRI), FIB4 or TE, with biopsy as a reference, in patients with chronic hepatitis C (CHC) or B (CHB). Investigators abstracted and checked study details and quality by using pre-defined criteria. Bayesian method in intention to diagnose was the primary outcome.
resultsOf 1321 articles identified, 71 studies including 77 groups according to aetiology (All-CB) were eligible: 37 Only-C, 28 Only-B and 12 Mixed-C-B. There were 185 direct comparisons between the area under the ROC curves (AUROCs), 99 for the diagnosis of advanced fibrosis and 86 for cirrhosis. In All-CB, Bayesian analyses revealed significant AUROCs differences in identifying advanced fibrosis in favour of FibroTest vs. TE [credibility interval: 0.06(0.02-0.09)], FibroTest vs. APRI [0.05 (0.03-0.07)] and for identifying cirrhosis TE vs. APRI [0.07 (0.02-0.13)] and FIB4 vs. APRI [0.04(0.02-0.05)]. No differences were observed between TE and FibroTest, for identifying cirrhosis in All-CB, and in sub-groups (Only-C, Only-B, Mixed-CB) for both cirrhosis and fibrosis.
conclusionsIn CHC and CHB, APRI had lower performances than FIB-4, TE and FibroTest. TE had lower performance than FibroTest for identifying advanced fibrosis in All-CB, without significant difference for identifying cirrhosis in all groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.